Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib in Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT05676697Phase 1Terminated
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of linperlisib in autoimmune hemolytic anemia (AIHA), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Overall response rate. Started Jan 2023; status: terminated.
02
Drugs
linperlisib
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT05676697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05676697.